Form D · Pharmaceuticals
Apertor Pharmaceuticals, Inc.
New York, NY · CIK 0001832728
Offering snapshot reported Nov 17, 2020 · SEC filing
- Reported sold
- $3M Offering amount: $50M
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Nov 5, 2020 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Nov 17, 2020 | Initial | $3,000,000 | No comparison | 1 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-380841
Source: Form D, filed Nov 17, 2020. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Robert T. Abraham | Director |
| Paul Eisenberg | Director |
| Edmund Graziani | Director, Executive |
| Seth Harrison | Director |
| Spiros Liras | Director, Executive |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
230 Park Avenue Suite 2800
New York, NY, 10169
New York, NY, 10169